RU2495031C2 - Производные 5-(4-метансульфонилфенил)тиазола для лечения острых и хронических воспалительных заболеваний - Google Patents

Производные 5-(4-метансульфонилфенил)тиазола для лечения острых и хронических воспалительных заболеваний Download PDF

Info

Publication number: RU2495031C2
Authority: RU; Russia
Prior art keywords: compound; production; tnf; alpha; cells
Prior art date: 2008-06-16

Application number

RU2011101439/04A

Other languages

English (en)

Russian (ru)

Other versions

RU2011101439A (ru

Inventor

РОЙО Виктор РУБИО

ЛА ЭРА МАРТИНЕС Антонио ДЕ

ДЕ МОН СОТО Мельчор АЛЬВАРЕС

МУНЬОС Ана МУНЬОС

Original Assignee

Фаэс Фарма, С.А.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-16

Filing date

2009-06-15

Publication date

2013-10-10

2008-06-16 Priority claimed from EP08380177A external-priority patent/EP2135864A1/en

2008-06-16 Priority claimed from US12/139,661 external-priority patent/US7781594B2/en

2009-06-15 Application filed by Фаэс Фарма, С.А. filed Critical Фаэс Фарма, С.А.

2012-07-27 Publication of RU2011101439A publication Critical patent/RU2011101439A/ru

2013-10-10 Application granted granted Critical

2013-10-10 Publication of RU2495031C2 publication Critical patent/RU2495031C2/ru

Links

230000001154 acute effect Effects 0.000 title claims abstract description 25
208000037976 chronic inflammation Diseases 0.000 title claims abstract description 21
208000037893 chronic inflammatory disorder Diseases 0.000 title claims abstract description 21
208000030090 Acute Disease Diseases 0.000 title claims abstract description 20
ZSYQCVZWUMOZJW-UHFFFAOYSA-N 5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical class C1=CC(S(=O)(=O)C)=CC=C1C1=CN=CS1 ZSYQCVZWUMOZJW-UHFFFAOYSA-N 0.000 title abstract description 3
238000004519 manufacturing process Methods 0.000 claims abstract description 148
150000001875 compounds Chemical class 0.000 claims abstract description 130
108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 116
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 107
108010074328 Interferon-gamma Proteins 0.000 claims abstract description 85
102000004127 Cytokines Human genes 0.000 claims abstract description 73
108090000695 Cytokines Proteins 0.000 claims abstract description 73
108090001007 Interleukin-8 Proteins 0.000 claims abstract description 70
108090000174 Interleukin-10 Proteins 0.000 claims abstract description 47
102000003814 Interleukin-10 Human genes 0.000 claims abstract description 47
239000003814 drug Substances 0.000 claims abstract description 44
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 20
230000002519 immonomodulatory effect Effects 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 14
230000001105 regulatory effect Effects 0.000 claims abstract description 13
229910052736 halogen Inorganic materials 0.000 claims abstract description 8
230000002401 inhibitory effect Effects 0.000 claims abstract description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 7
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
102100037850 Interferon gamma Human genes 0.000 claims abstract description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
125000005842 heteroatom Chemical group 0.000 claims abstract description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 3
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 5
125000005843 halogen group Chemical group 0.000 claims abstract 3
239000003085 diluting agent Substances 0.000 claims description 95
206010039073 rheumatoid arthritis Diseases 0.000 claims description 61
238000011282 treatment Methods 0.000 claims description 22
208000027866 inflammatory disease Diseases 0.000 claims description 13
230000000770 proinflammatory effect Effects 0.000 claims description 12
230000009885 systemic effect Effects 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
206010040070 Septic Shock Diseases 0.000 claims description 8
230000036303 septic shock Effects 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 7
206010040047 Sepsis Diseases 0.000 claims description 6
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
208000006454 hepatitis Diseases 0.000 claims description 5
231100000283 hepatitis Toxicity 0.000 claims description 5
206010025135 lupus erythematosus Diseases 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 4
229910052717 sulfur Chemical group 0.000 claims description 4
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
239000011593 sulfur Chemical group 0.000 claims description 3
230000000694 effects Effects 0.000 abstract description 62
239000000126 substance Substances 0.000 abstract description 33
229940124597 therapeutic agent Drugs 0.000 abstract description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
239000005864 Sulphur Substances 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 131
229940125797 compound 12 Drugs 0.000 description 118
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 117
239000002158 endotoxin Substances 0.000 description 117
229920006008 lipopolysaccharide Polymers 0.000 description 117
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 116
102000008070 Interferon-gamma Human genes 0.000 description 80
229960003130 interferon gamma Drugs 0.000 description 80
102000004890 Interleukin-8 Human genes 0.000 description 66
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 66
229940096397 interleukin-8 Drugs 0.000 description 64
210000005259 peripheral blood Anatomy 0.000 description 46
239000011886 peripheral blood Substances 0.000 description 46
210000001616 monocyte Anatomy 0.000 description 41
229940076144 interleukin-10 Drugs 0.000 description 40
230000028327 secretion Effects 0.000 description 39
238000002474 experimental method Methods 0.000 description 33
238000004113 cell culture Methods 0.000 description 32
229940079593 drug Drugs 0.000 description 32
239000003153 chemical reaction reagent Substances 0.000 description 31
230000002269 spontaneous effect Effects 0.000 description 30
150000003839 salts Chemical class 0.000 description 29
230000000638 stimulation Effects 0.000 description 29
239000002904 solvent Substances 0.000 description 28
239000001963 growth medium Substances 0.000 description 27
239000002609 medium Substances 0.000 description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
210000002966 serum Anatomy 0.000 description 23
239000012453 solvate Substances 0.000 description 23
201000010099 disease Diseases 0.000 description 22
238000000034 method Methods 0.000 description 22
239000000651 prodrug Substances 0.000 description 22
229940002612 prodrug Drugs 0.000 description 22
-1 for example Proteins 0.000 description 21
230000014509 gene expression Effects 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 19
239000012228 culture supernatant Substances 0.000 description 19
238000004458 analytical method Methods 0.000 description 18
238000005516 engineering process Methods 0.000 description 18
108020004999 messenger RNA Proteins 0.000 description 18
238000005160 1H NMR spectroscopy Methods 0.000 description 17
108010004729 Phycoerythrin Proteins 0.000 description 17
230000005764 inhibitory process Effects 0.000 description 17
235000008935 nutritious Nutrition 0.000 description 17
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
101001018097 Homo sapiens L-selectin Proteins 0.000 description 16
102100033467 L-selectin Human genes 0.000 description 16
230000002757 inflammatory effect Effects 0.000 description 16
230000006433 tumor necrosis factor production Effects 0.000 description 16
108010047620 Phytohemagglutinins Proteins 0.000 description 14
238000011161 development Methods 0.000 description 14
230000018109 developmental process Effects 0.000 description 14
229910052739 hydrogen Inorganic materials 0.000 description 14
239000001257 hydrogen Substances 0.000 description 14
210000004698 lymphocyte Anatomy 0.000 description 14
230000001885 phytohemagglutinin Effects 0.000 description 14
239000000243 solution Substances 0.000 description 14
210000000056 organ Anatomy 0.000 description 13
238000012360 testing method Methods 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
239000000047 product Substances 0.000 description 12
239000000523 sample Substances 0.000 description 12
108010002350 Interleukin-2 Proteins 0.000 description 11
230000009471 action Effects 0.000 description 11
229940125898 compound 5 Drugs 0.000 description 11
238000007912 intraperitoneal administration Methods 0.000 description 11
239000000203 mixture Substances 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 10
238000005481 NMR spectroscopy Methods 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 10
201000004681 Psoriasis Diseases 0.000 description 10
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 10
230000004913 activation Effects 0.000 description 10
125000000753 cycloalkyl group Chemical group 0.000 description 10
238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
150000002431 hydrogen Chemical class 0.000 description 10
230000028993 immune response Effects 0.000 description 10
230000002062 proliferating effect Effects 0.000 description 10
IPDRTIBDOPMMIQ-VAOFZXAKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C)O[C@H](CO)[C@@H](O)C1 IPDRTIBDOPMMIQ-VAOFZXAKSA-N 0.000 description 9
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
210000000612 antigen-presenting cell Anatomy 0.000 description 9
239000011324 bead Substances 0.000 description 9
229940126142 compound 16 Drugs 0.000 description 9
230000009696 proliferative response Effects 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
108010062580 Concanavalin A Proteins 0.000 description 8
238000002965 ELISA Methods 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
125000003118 aryl group Chemical group 0.000 description 8
238000003384 imaging method Methods 0.000 description 8
230000006698 induction Effects 0.000 description 8
230000002297 mitogenic effect Effects 0.000 description 8
239000000546 pharmaceutical excipient Substances 0.000 description 8
230000008569 process Effects 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
208000023275 Autoimmune disease Diseases 0.000 description 7
241000282414 Homo sapiens Species 0.000 description 7
206010028851 Necrosis Diseases 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
206010014599 encephalitis Diseases 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
230000017074 necrotic cell death Effects 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
201000001320 Atherosclerosis Diseases 0.000 description 6
102000019034 Chemokines Human genes 0.000 description 6
108010012236 Chemokines Proteins 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
239000000090 biomarker Substances 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
230000001684 chronic effect Effects 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
238000009826 distribution Methods 0.000 description 6
239000008103 glucose Substances 0.000 description 6
239000008187 granular material Substances 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000003902 lesion Effects 0.000 description 6
238000011002 quantification Methods 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
238000005406 washing Methods 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
108090001005 Interleukin-6 Proteins 0.000 description 5
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
208000037273 Pathologic Processes Diseases 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
239000008186 active pharmaceutical agent Substances 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
238000003556 assay Methods 0.000 description 5
208000010668 atopic eczema Diseases 0.000 description 5
230000003833 cell viability Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
229940088679 drug related substance Drugs 0.000 description 5
150000002367 halogens Chemical class 0.000 description 5
102000057041 human TNF Human genes 0.000 description 5
210000002865 immune cell Anatomy 0.000 description 5
229960003444 immunosuppressant agent Drugs 0.000 description 5
239000003018 immunosuppressive agent Substances 0.000 description 5
238000009434 installation Methods 0.000 description 5
230000031261 interleukin-10 production Effects 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
210000005087 mononuclear cell Anatomy 0.000 description 5
230000009054 pathological process Effects 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
108010086652 phytohemagglutinin-P Proteins 0.000 description 5
238000007619 statistical method Methods 0.000 description 5
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
206010012438 Dermatitis atopic Diseases 0.000 description 4
206010018364 Glomerulonephritis Diseases 0.000 description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 4
206010036030 Polyarthritis Diseases 0.000 description 4
208000004403 Prostatic Hyperplasia Diseases 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
208000006045 Spondylarthropathies Diseases 0.000 description 4
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
230000006052 T cell proliferation Effects 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
102100040247 Tumor necrosis factor Human genes 0.000 description 4
206010046851 Uveitis Diseases 0.000 description 4
238000000149 argon plasma sintering Methods 0.000 description 4
201000008937 atopic dermatitis Diseases 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229940125773 compound 10 Drugs 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
230000002134 immunopathologic effect Effects 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
238000002372 labelling Methods 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
150000004702 methyl esters Chemical class 0.000 description 4
239000011859 microparticle Substances 0.000 description 4
239000003226 mitogen Substances 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
201000008482 osteoarthritis Diseases 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
229960001052 streptozocin Drugs 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
239000000725 suspension Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
239000003826 tablet Substances 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
101100398412 Arabidopsis thaliana ASK1 gene Proteins 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
206010006895 Cachexia Diseases 0.000 description 3
229940126657 Compound 17 Drugs 0.000 description 3
208000016192 Demyelinating disease Diseases 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
238000008157 ELISA kit Methods 0.000 description 3
208000037487 Endotoxemia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920001917 Ficoll Polymers 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
201000009906 Meningitis Diseases 0.000 description 3
208000001145 Metabolic Syndrome Diseases 0.000 description 3
208000034486 Multi-organ failure Diseases 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
108090000340 Transaminases Proteins 0.000 description 3
102000003929 Transaminases Human genes 0.000 description 3
206010048302 Tubulointerstitial nephritis Diseases 0.000 description 3
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
208000024780 Urticaria Diseases 0.000 description 3
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
206010002022 amyloidosis Diseases 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
230000003305 autocrine Effects 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
229940125758 compound 15 Drugs 0.000 description 3
201000003146 cystitis Diseases 0.000 description 3
230000007850 degeneration Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000012636 effector Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
210000004969 inflammatory cell Anatomy 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000021995 interleukin-8 production Effects 0.000 description 3
201000006334 interstitial nephritis Diseases 0.000 description 3
210000001503 joint Anatomy 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
201000011475 meningoencephalitis Diseases 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 3
206010028417 myasthenia gravis Diseases 0.000 description 3
239000013642 negative control Substances 0.000 description 3
230000003076 paracrine Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
210000004976 peripheral blood cell Anatomy 0.000 description 3
208000027232 peripheral nervous system disease Diseases 0.000 description 3
208000033808 peripheral neuropathy Diseases 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
208000030428 polyarticular arthritis Diseases 0.000 description 3
239000013641 positive control Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000002265 prevention Effects 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 3
201000000306 sarcoidosis Diseases 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000004611 spectroscopical analysis Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
150000003556 thioamides Chemical class 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
238000005303 weighing Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
AHMLFHMRRBJCRM-UHFFFAOYSA-N 2-(4-methylsulfanylphenyl)acetic acid Chemical compound CSC1=CC=C(CC(O)=O)C=C1 AHMLFHMRRBJCRM-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
108091007505 ADAM17 Proteins 0.000 description 2
102000043279 ADAM17 Human genes 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010003399 Arthropod bite Diseases 0.000 description 2
241001227713 Chiron Species 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
206010011968 Decreased immune responsiveness Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
108700027089 Hirudo medicinalis macrolin Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
101100046526 Mus musculus Tnf gene Proteins 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
238000001190 Q-PCR Methods 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
206010040844 Skin exfoliation Diseases 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
208000018359 Systemic autoimmune disease Diseases 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
210000000447 Th1 cell Anatomy 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
102000002689 Toll-like receptor Human genes 0.000 description 2
108020000411 Toll-like receptor Proteins 0.000 description 2
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
238000013019 agitation Methods 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
230000003321 amplification Effects 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000012754 cardiac puncture Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000004737 colorimetric analysis Methods 0.000 description 2
230000004940 costimulation Effects 0.000 description 2
230000000139 costimulatory effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
238000006352 cycloaddition reaction Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000035618 desquamation Effects 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
230000009266 disease activity Effects 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000009509 drug development Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
210000002310 elbow joint Anatomy 0.000 description 2
239000003480 eluent Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000011152 fibreglass Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
210000004349 growth plate Anatomy 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
230000036541 health Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
208000023589 ischemic disease Diseases 0.000 description 2
229960002725 isoflurane Drugs 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012022 methylating agents‎ Substances 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
230000003448 neutrophilic effect Effects 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
230000008816 organ damage Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
208000008494 pericarditis Diseases 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
201000007094 prostatitis Diseases 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
229950005741 rolipram Drugs 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000035807 sensation Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
241000894007 species Species 0.000 description 2
238000010186 staining Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
206010043778 thyroiditis Diseases 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
229910052722 tritium Inorganic materials 0.000 description 2
108010072415 tumor necrosis factor precursor Proteins 0.000 description 2
230000035899 viability Effects 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
SYXIINHHRQQNGK-UHFFFAOYSA-N 1,3-thiazol-4-ol Chemical compound [O-]C1=CSC=[NH+]1 SYXIINHHRQQNGK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LWMBPKJYEQGDLN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;piperazine;hydrate Chemical compound O.C1CNCCN1.C1CNCCN1.C1CNCCN1.OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O LWMBPKJYEQGDLN-UHFFFAOYSA-N 0.000 description 1
YVNVWIGXULADLD-UHFFFAOYSA-N 2-methyl-5-(4-methylsulfonylphenyl)-1,3-thiazol-4-ol Chemical compound S1C(C)=NC(O)=C1C1=CC=C(S(C)(=O)=O)C=C1 YVNVWIGXULADLD-UHFFFAOYSA-N 0.000 description 1
RCNOGGGBSSVMAS-UHFFFAOYSA-N 2-thiophen-3-ylacetic acid Chemical compound OC(=O)CC=1C=CSC=1 RCNOGGGBSSVMAS-UHFFFAOYSA-N 0.000 description 1
CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical compound OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 description 1
DCPLSZRONTVIIH-UHFFFAOYSA-N 4-cyclopentyloxy-2-methyl-5-(4-methylsulfonylphenyl)-1,3-thiazole Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1SC(C)=NC=1OC1CCCC1 DCPLSZRONTVIIH-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010062269 Adrenalitis Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
108010082126 Alanine transaminase Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
101000878581 Aplysia californica Feeding circuit activating peptides Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WQXHCQQCHAQDEK-UHFFFAOYSA-N BrC(C(=O)O)C1=CC=C(C=C1)S(=O)(=O)C Chemical compound BrC(C(=O)O)C1=CC=C(C=C1)S(=O)(=O)C WQXHCQQCHAQDEK-UHFFFAOYSA-N 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
UDYKEEXCCYPELM-UHFFFAOYSA-N C=CS(c(cc1)ccc1-c([s]c(CI)n1)c1OI)(=O)=O Chemical compound C=CS(c(cc1)ccc1-c([s]c(CI)n1)c1OI)(=O)=O UDYKEEXCCYPELM-UHFFFAOYSA-N 0.000 description 1
101150085479 CHS2 gene Proteins 0.000 description 1
0 CS(c(cc1)ccc1-c([s]c(*)n1)c1OC1CCCC1)(=O)=O Chemical compound CS(c(cc1)ccc1-c([s]c(*)n1)c1OC1CCCC1)(=O)=O 0.000 description 1
NEGXCABIWRXCCT-UHFFFAOYSA-N CS(c(cc1)ccc1-c([s]c(-c(cccc1)c1Cl)n1)c1OC1CCCC1)(=O)=O Chemical compound CS(c(cc1)ccc1-c([s]c(-c(cccc1)c1Cl)n1)c1OC1CCCC1)(=O)=O NEGXCABIWRXCCT-UHFFFAOYSA-N 0.000 description 1
WOKMLSXTRDHCAW-UHFFFAOYSA-N CS(c(cc1)ccc1-c([s]c(C1CCCCC1)n1)c1OC1CCCC1)(=O)=O Chemical compound CS(c(cc1)ccc1-c([s]c(C1CCCCC1)n1)c1OC1CCCC1)(=O)=O WOKMLSXTRDHCAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000811217 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S19e Proteins 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
102000003777 Interleukin-1 beta Human genes 0.000 description 1
108090000193 Interleukin-1 beta Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
102100026236 Interleukin-8 Human genes 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
108010092694 L-Selectin Proteins 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
102000016551 L-selectin Human genes 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
208000011623 Obstructive Lung disease Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
241001303601 Rosacea Species 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
101150033527 TNF gene Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102100039360 Toll-like receptor 4 Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
229960001931 ampicillin sodium Drugs 0.000 description 1
KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
230000003092 anti-cytokine Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
150000005840 aryl radicals Chemical class 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000035584 blastogenesis Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000012503 blood component Substances 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000006059 cover glass Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013058 crude material Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
KDUIUFJBNGTBMD-UHFFFAOYSA-N cyclooctatetraene Chemical compound C1=CC=CC=CC=C1 KDUIUFJBNGTBMD-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000013480 data collection Methods 0.000 description 1
238000010908 decantation Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
235000019621 digestibility Nutrition 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000028023 exocytosis Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003633 gene expression assay Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000008938 immune dysregulation Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
HCMUPMCWKYOOBZ-UHFFFAOYSA-N methyl 2-(4-methylsulfonylphenyl)acetate Chemical compound COC(=O)CC1=CC=C(S(C)(=O)=O)C=C1 HCMUPMCWKYOOBZ-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
238000000491 multivariate analysis Methods 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000002547 new drug Substances 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940029358 orthoclone okt3 Drugs 0.000 description 1
230000001151 other effect Effects 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000032390 pattern recognition receptor signaling pathway Effects 0.000 description 1
108010089193 pattern recognition receptors Proteins 0.000 description 1
102000007863 pattern recognition receptors Human genes 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
108010086662 phytohemagglutinin-M Proteins 0.000 description 1
229960005141 piperazine Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
230000007114 proinflammatory cascade Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
208000014731 pulmonary artery disease Diseases 0.000 description 1
208000037826 rabdomyosarcoma Diseases 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000008672 reprogramming Effects 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000004700 rosacea Diseases 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000007614 solvation Methods 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008409 synovial inflammation Effects 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000000101 thioether group Chemical group 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000000287 tissue oxygenation Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
239000002525 vasculotropin inhibitor Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Dermatology (AREA)
Neurology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)

RU2011101439/04A 2008-06-16 2009-06-15 Производные 5-(4-метансульфонилфенил)тиазола для лечения острых и хронических воспалительных заболеваний RU2495031C2 (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP08380177.9		2008-06-16
EP08380177A EP2135864A1 (en)	2008-06-16	2008-06-16	5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
US12/139,661		2008-06-16
US12/139,661 US7781594B2 (en)	2008-06-16	2008-06-16	5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
PCT/EP2009/057324 WO2009153226A1 (en)	2008-06-16	2009-06-15	5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases

Publications (2)

Publication Number	Publication Date
RU2011101439A RU2011101439A (ru)	2012-07-27
RU2495031C2 true RU2495031C2 (ru)	2013-10-10

Family

ID=43414178

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2011101439/04A RU2495031C2 (ru)	2008-06-16	2009-06-15	Производные 5-(4-метансульфонилфенил)тиазола для лечения острых и хронических воспалительных заболеваний

Country Status (19)

Country	Link
EP (1)	EP2313382A1 (es)
JP (1)	JP2011524352A (es)
KR (1)	KR20110022679A (es)
CN (1)	CN102083806A (es)
AR (1)	AR072113A1 (es)
AU (1)	AU2009259451B2 (es)
BR (1)	BRPI0915325A2 (es)
CA (1)	CA2728139A1 (es)
CO (1)	CO6331429A2 (es)
IL (1)	IL209801A0 (es)
MA (1)	MA32473B1 (es)
MX (1)	MX2010013978A (es)
NZ (1)	NZ589894A (es)
RU (1)	RU2495031C2 (es)
SA (1)	SA109300384B1 (es)
TW (1)	TWI403506B (es)
UY (1)	UY31896A (es)
WO (1)	WO2009153226A1 (es)
ZA (1)	ZA201008877B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2961695B1 (fr) *	2010-06-29	2012-07-06	Galderma Res & Dev	Utilisation de composes dans le traitement ou la prevention de troubles cutanes
RU2502513C2 (ru) *	2012-01-11	2013-12-27	Государственное бюджетное учреждение здравоохранения Свердловской области "Свердловский областной клинический психоневрологический госпиталь для ветеранов войн" (ГБУЗ СО "СОКП Госпиталь для ветеранов войн")	Способ лечения больных с полиорганной патологией озонотерапией
BR112020009477A2 (pt) *	2017-11-23	2020-11-03	Immunic Ag	compostos e regime de dosagem para uso na prevenção ou tratamento de doenças inflamatórias e/ou autoimunes
KR102076936B1 (ko) *	2019-08-12	2020-02-13	연세대학교 산학협력단	티아졸 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물
IT202000008125A1 (it) *	2020-04-16	2021-10-16	Minerva Srl	Acidi carbossilici 3-aza-biciclo[3.2.1]ottani e loro derivati per l’uso nel trattamento di infiammazioni

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5124342A (en) *	1989-02-08	1992-06-23	Abbott Laboratories	4-hydroxythiazoles as 5-lipoxygenase inhibitors
WO2001027094A1 (en) *	1999-10-12	2001-04-19	Japan Tobacco Inc.	Hypertriglyceridemia remedies and antiobestics
US20050026902A1 (en) *	2003-01-31	2005-02-03	Timothy Maziasz	Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
EA007933B1 (ru) *	2001-08-13	2007-02-27	Янссен Фармацевтика Н.В.	2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH10504542A (ja) *	1994-07-27	1998-05-06	ジー．ディー．サールアンドカンパニー	炎症処置用の置換チアゾール化合物
DE69635048T2 (de) *	1995-06-12	2006-02-16	G.D. Searle & Co.	Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

2009
- 2009-06-06 TW TW098118927A patent/TWI403506B/zh not_active IP Right Cessation
- 2009-06-12 UY UY0001031896A patent/UY31896A/es not_active Application Discontinuation
- 2009-06-12 AR ARP090102121A patent/AR072113A1/es unknown
- 2009-06-15 JP JP2011513001A patent/JP2011524352A/ja active Pending
- 2009-06-15 BR BRPI0915325A patent/BRPI0915325A2/pt not_active IP Right Cessation
- 2009-06-15 CA CA2728139A patent/CA2728139A1/en not_active Abandoned
- 2009-06-15 KR KR1020117001228A patent/KR20110022679A/ko not_active Ceased
- 2009-06-15 SA SA109300384A patent/SA109300384B1/ar unknown
- 2009-06-15 EP EP09765806A patent/EP2313382A1/en not_active Withdrawn
- 2009-06-15 WO PCT/EP2009/057324 patent/WO2009153226A1/en not_active Ceased
- 2009-06-15 AU AU2009259451A patent/AU2009259451B2/en not_active Ceased
- 2009-06-15 CN CN2009801226820A patent/CN102083806A/zh active Pending
- 2009-06-15 MX MX2010013978A patent/MX2010013978A/es active IP Right Grant
- 2009-06-15 RU RU2011101439/04A patent/RU2495031C2/ru not_active IP Right Cessation
- 2009-06-15 NZ NZ589894A patent/NZ589894A/en not_active IP Right Cessation
2010
- 2010-12-06 IL IL209801A patent/IL209801A0/en unknown
- 2010-12-09 ZA ZA2010/08877A patent/ZA201008877B/en unknown
2011
- 2011-01-13 MA MA33516A patent/MA32473B1/fr unknown
- 2011-01-14 CO CO11003796A patent/CO6331429A2/es active IP Right Grant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5124342A (en) *	1989-02-08	1992-06-23	Abbott Laboratories	4-hydroxythiazoles as 5-lipoxygenase inhibitors
WO2001027094A1 (en) *	1999-10-12	2001-04-19	Japan Tobacco Inc.	Hypertriglyceridemia remedies and antiobestics
EA007933B1 (ru) *	2001-08-13	2007-02-27	Янссен Фармацевтика Н.В.	2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
US20050026902A1 (en) *	2003-01-31	2005-02-03	Timothy Maziasz	Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCIS A.J. KERDESKY et al.: "4-Hydroxythiazole inhibitors of 5-lipoxygenase", J. Med. Chem., 1991, vol.34, no.7, p.2158-2165. *
JACQUES YVES GAUTHIER et al.: "Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 inhibitors. Part II: Replacing the heterocycle", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, vol.6, no.1, p.87-92. *
MARYVONNE FERREY et al.: "A new synthesis of 4-hydroxythiazoles", SYNTHESIS, 1976, no.4, p.261-262. *
MARYVONNE FERREY et al.: "A new synthesis of 4-hydroxythiazoles", SYNTHESIS, 1976, no.4, p.261-262. JACQUES YVES GAUTHIER et al.: "Synthesis and biological evaluation of 2,3-diarylthiophenes as selective COX-2 inhibitors. Part II: Replacing the heterocycle", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, vol.6, no.1, p.87-92. FRANCIS A.J. KERDESKY et al.: "4-Hydroxythiazole inhibitors of 5-lipoxygenase", J. Med. Chem., 1991, vol.34, no.7, p.2158-2165. *

Also Published As

Publication number	Publication date
MX2010013978A (es)	2011-03-29
NZ589894A (en)	2011-08-26
RU2011101439A (ru)	2012-07-27
EP2313382A1 (en)	2011-04-27
CN102083806A (zh)	2011-06-01
TWI403506B (zh)	2013-08-01
SA109300384B1 (ar)	2013-04-20
CO6331429A2 (es)	2011-10-20
KR20110022679A (ko)	2011-03-07
AR072113A1 (es)	2010-08-04
AU2009259451A1 (en)	2009-12-23
BRPI0915325A2 (pt)	2015-10-27
ZA201008877B (en)	2012-02-29
UY31896A (es)	2010-01-29
AU2009259451B2 (en)	2013-03-14
CA2728139A1 (en)	2009-12-23
WO2009153226A1 (en)	2009-12-23
IL209801A0 (en)	2011-02-28
JP2011524352A (ja)	2011-09-01
MA32473B1 (fr)	2011-07-03
TW201010988A (en)	2010-03-16

Publication	Publication Date	Title
US12071424B2 (en)	2024-08-27	IRE1 small molecule inhibitors
JP2021073302A (ja)	2021-05-13	メチル／フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物
JP5426813B2 (ja)	2014-02-26	強力な抗糖尿病薬化合物の塩および多形体
RU2495031C2 (ru)	2013-10-10	Производные 5-(4-метансульфонилфенил)тиазола для лечения острых и хронических воспалительных заболеваний
WO2020155931A1 (zh)	2020-08-06	一种jak抑制剂及其制备方法
JP2019533642A (ja)	2019-11-21	Ｇｐｒ１２０モジュレーターとして有用な二環式化合物
ES2427726T3 (es)	2013-10-31	Nuevos difeniléteres heterocíclicos
KR20210027382A (ko)	2021-03-10	접히지 않은 단백질 반응의 활성화제
CN101861149A (zh)	2010-10-13	用于治疗肥胖症、糖尿病和心血管疾病的n-(2-噻唑基)-酰胺衍生物
US8492411B2 (en)	2013-07-23	5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
CN110049973B (zh)	2023-02-17	1,4-二苯基-1h-咪唑和2，4-二苯基噻唑类衍生物及其制备方法和用途
US8809555B2 (en)	2014-08-19	Anti-leishmanial compound and anti-leishmanial drug
EP2135864A1 (en)	2009-12-23	5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
WO2008018692A1 (en)	2008-02-14	Novel chalcone derivatives which inhibit the il-5 activity
TW202425981A (zh)	2024-07-01	含磷化合物、藥物組合物及其應用
US8373006B2 (en)	2013-02-12	Anti-leishmanial compound and anti-leishmanial drug
CN112679409A (zh)	2021-04-20	一种4-吲哚-取代硫半脲衍生物及其制备方法和应用
TWI811901B (zh)	2023-08-11	一種嘧啶甲醯胺類化合物及其應用
HK1157325A (en)	2012-06-29	5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
RU2246486C1 (ru)	2005-02-20	Комплекс n,n-диэтилдитиокарбамата натрия с 2-этил-6-метил-3-гидроксипиридином, обладающий противоаллергической активностью
US20170327470A1 (en)	2017-11-16	Novel hydrosoluble compounds derived from benzimidazole used in treating fasciolosis
KR100529692B1 (ko)	2005-11-17	인터루킨-5 억제효과를 갖는 신규사이클로헥실아이소플라본논계 유도체
JP2022527641A (ja)	2022-06-02	Ｃｘｃｒ４モジュレーターとしてのイミダゾリン誘導体
WO2020140960A1 (zh)	2020-07-09	吲哚甲酰胺类衍生物的晶型及其制备方法
JP2007228808A (ja)	2007-09-13	自己免疫疾患の予防及び／又は治療剤の有効成分の同定方法

Legal Events

Date	Code	Title	Description
2016-02-20	MM4A	The patent is invalid due to non-payment of fees	Effective date: 20150616